Quipt Home Medical Corp. filings document the company's respiratory home medical equipment business, public-company governance and the corporate-status transition following its completed arrangement. 8-K disclosures recorded operating results prepared under GAAP, non-GAAP reconciliations furnished with earnings materials, shareholder voting matters, material agreements, capital-structure information and material-event updates.
Later Exchange Act filings documented the removal of QIPT common shares from Nasdaq listing and registration on Form 25 and the Form 15 certification to terminate or suspend reporting obligations for the common shares. The Form 15 record identified one holder of record and no remaining class of securities with a continuing Section 13(a) or 15(d) reporting duty.
Quipt Home Medical Corp. announced a press release furnished on August 11, 2025 reporting its financial results for the quarter ended June 30, 2025. The filing states the press release is furnished as Exhibit 99.1 and that the information is furnished, not filed, under the Exchange Act.
The company discloses the press release includes Non-GAAP financial measures along with GAAP comparatives and reconciliations and explains management believes these measures provide useful supplemental information. The 8-K is signed by CFO Hardik Mehta and identifies Quipt as an emerging growth company incorporated in British Columbia, Canada.
Quipt Home Medical Corp. reported results for the quarter and nine months ended June 30, 2025. Revenue for the quarter was $58.3 million, down 4.1% from $60.8 million a year earlier, and nine-month revenue was $177.0 million versus $184.6 million. The company recorded a quarterly net loss of $3.0 million (basic loss per share $0.07) and a nine-month net loss of $7.2 million (basic loss per share $0.17), both larger than the prior-year periods. Adjusted EBITDA remained positive at $13.7 million for the quarter and $41.0 million for nine months.
Quipt ended the period with $11.25 million of cash and total assets of $236.1 million against total liabilities of $133.6 million. The Company was in compliance with its senior credit facility covenants and had $66.0 million principal outstanding under that facility. Management disclosed a DOJ civil investigative demand related to CPAP claims and noted the SEC concluded its inquiry in November 2024. After period end, Quipt acquired Mediserve for approximately $2.6 million. The Company performed an interim goodwill impairment test following market declines and identified no impairment.